Related Experiment Video
Updated: Aug 6, 2025
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
SENHANCE ROBOTIC RADICAL PROSTATECTOMY
Tomislav Kuliš1,2, Tvrtko Hudolin1,2, Luka Penezić1
1Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia.
Abstract:
Since its introduction 20 years ago, robotic radical prostatectomy has become a standard of care in the treatment of localized prostate cancer in many Centers. Until recently, they have all been performed by the only available robotic platform. Senhance is a novel robotic platform that was approved for clinical use. The term Senhance was used to systematically search PubMed and Scopus databases for relevant articles that were afterward filtered for appropriate designs and data reports. There were two reports that met all of the criteria and were included in the review. Both studies were designed as prospective case series with a total of 234 patients where the data including operative data and oncological outcomes were reported. The average operative time ranged between 180 and 195 min, with estimated blood loss between 250 and 300 mL. There was 3 Clavien - Dindo grade III, and 1 Clavien - DIndo grade IV complication reported. One of the studies compared it with laparoscopy, but no significant difference in operative time and blood loss was found. Both studies concluded that the Senhance is a feasible and safe robotic platform for radical prostatectomy.
Insights
The Senhance robotic platform is a new, feasible, and safe option for robotic radical prostatectomy in localized prostate cancer treatment. Studies show comparable operative times and blood loss to existing methods.
Area of Science:
- Urology
- Surgical Technology
- Oncology
Background:
- Robotic radical prostatectomy is a standard treatment for localized prostate cancer.
- Historically, a single robotic platform dominated the field.
- The Senhance system represents a novel alternative for robotic surgery.
Purpose of the Study:
- To review the initial clinical experience with the Senhance robotic platform for radical prostatectomy.
- To assess the feasibility, safety, and oncological outcomes of the Senhance system.
Main Methods:
- Systematic literature search of PubMed and Scopus databases using the term "Senhance".
- Inclusion of prospective case series reporting operative data and oncological outcomes.
- Analysis of data from two studies involving 234 patients.
Main Results:
- Average operative time ranged from 180 to 195 minutes.
- Estimated blood loss was between 250 and 300 mL.
- Reported complications included 3 Clavien-Dindo grade III and 1 grade IV.
Conclusions:
- The Senhance robotic platform is a feasible and safe option for radical prostatectomy.
- Initial outcomes suggest comparable performance to existing laparoscopic approaches.
- Further research may validate its role in prostate cancer treatment.
